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Psychosocial and pharmacological treatments for cannabis use disorder and mental 
health comorbidities: a narrative review 
 
Abstract 
Cannabis is the most widely used illicit drug worldwide, and it is estimated that up to 30% of 
people who use cannabis will develop a Cannabis Use Disorder (CUD). Treatment demand for 
CUD is increasing in almost every world region and cannabis use is highly comorbid with 
mental disorders, where sustained use can reduce treatment compliance and increase risk of 
relapse. In this narrative review, we outline evidence for psychosocial and pharmacological 
treatment strategies for CUD, both alone and when comorbid with psychosis, anxiety or 
depression. Psychosocial treatments such as CBT, MET and contingency management are 
currently the most effective strategy for treating CUD but are of limited benefit when comorbid 
with psychosis. Pharmacological treatments targeting the endocannabinoid system have the 
potential to reduce cannabis withdrawal and cannabis use in CUD. Mental health comorbidities 
including anxiety, depression and psychosis hinder effective treatment and should be addressed 
in treatment provision and clinical decision making to reduce the global burden of CUDs. 
Antipsychotic medication may decrease cannabis use and cannabis craving as well as psychotic 
symptoms in patients with CUD and psychosis. Targeted treatment for anxiety and depression 
when comorbid with CUD are feasible.  
 
Introduction 
Cannabis is the most commonly used illicit drug globally. It is estimated that approximately 
3.8% of the global population (188 million people) aged 15-64 used cannabis in the last year 
(UNODC, 2019). Cannabis use is especially prevalent in adolescents and young adults, with 
18% of European 15-24 year olds, compared to 7.4% of 25-64 year olds having tried cannabis 
in the past year (European Monitoring Centre for Drugs and Drug Addiction, 2019). Many 
people who use cannabis do so infrequently, and without major problems. However, 
epidemiological studies suggest that approximately 3 in 10 users go on to develop a 
problematic pattern of use characterised by continued use despite persistent adverse 
consequences (Hasin et al., 2015; Marel et al., 2019). Cannabis Use Disorder (CUD) refers to 
recurrent use of cannabis despite negative impact on the individual’s life, causing clinically 
significant impairment or distress (American Psychiatric Association, 2013). CUD replaced 
earlier diagnostic criteria of problematic use represented in DSM-IV-TR as separate diagnoses 
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for “Cannabis abuse” and “Cannabis dependence” which remain widely used in the literature 
at present.  
 
New medical and recreational cannabis laws, as well as increased discourse about cannabis and 
cannabinoids as medical products, have the potential to influence public perceptions of 
cannabis including the risks associated with its use. This could influence access to cannabis, as 
well as acceptability of treatment. However, despite public perception of the harmfulness of 
using cannabis decreasing over recent years (Hasin, 2018), the role of changing cannabis laws 
in this trend is unclear, (Keyes et al., 2016) and the impact this may have on treatment demand 
is also uncertain (Budney et al., 2019).  
 
Accumulating evidence suggests that CUDs are common and they often go untreated (Khan et 
al., 2013; Hasin et al., 2016; Kerridge et al., 2017). It is estimated that there are 22 million 
people worldwide with a cannabis use disorder (CUD), comparable to an estimated 27 million 
for opioid use disorders (Degenhardt et al., 2018), highlighting a clear clinical need for 
effective treatments. Regular cannabis use is associated with various negative mental health 
outcomes such as psychosis, anxiety and depression (Patton et al., 2002; Leadbeater et al., 
2019). Comorbidity between problematic cannabis use and other mental health disorders can 
create significant challenges for patients and treatment providers. 
 
In this narrative review, we discuss state-of-the-art clinical evidence on the treatment of CUDs. 
We begin by reviewing the latest evidence for psychosocial and pharmacological treatments. 
Next, we discuss treatments targeting CUDs comorbid with psychosis. This is a particularly 
important treatment need, given cannabis is used by an estimated 33.7% of people with first-
episode psychosis (Myles et al., 2016) and continued cannabis use is consistently associated 
with poorer clinical outcomes including longer hospital admissions, more severe positive 
symptoms (Schoeler et al., 2016) and poor medication adherence leading to relapse (Schoeler 
et al., 2017). Finally, we focus on treatments targeting CUD when comorbid with anxiety and 
depression. Anxiety and depression are common mental disorders, are highly comorbid with 
CUD (Hasin et al., 2016) and can influence treatment outcomes. For example, anxiety is 
associated with greater withdrawal symptom severity from cannabis use (Buckner et al., 2017) 
and depression is associated with lower likelihood of cannabis abstinence during a cessation 






Search Strategy and Selection Criteria 
Articles for this review were obtained from searching PubMed, PsychInfo, Google Scholar, 
Embase and Medline databases and the Cochrane Review database for key terms “Cannabis” 
“THC” “CUD” “Cannabis use disorder” “Psychosis” “Anxiety” “Depression” “Treatment” 
“Dual Diagnosis” from inception up to 24/02/2020. Additional articles were obtained from 
reference lists of existing papers and reviews. We searched the relevant grey literature 
(UNODC, EMCDDA) for the most up to date information on CUD internationally. RL ran 
the literature searches and consulted all authors on the inclusion of studies. We included 
studies that investigated psychosocial or pharmacological treatment options for CUD, 
including samples with and without comorbidities. Most of the included studies were 
randomized control trials (RCTs), although other experimental designs were included where 
RCTs had not been conducted or were inconclusive. Studies with both inpatient and 
outpatient designs were eligible. Trials were prioritized for inclusion based on methodology 
(such as large multisite RCTs) and novelty to the field. Where several trials of the same 
intervention had been conducted with converging results, we discuss the key trials. Studies 
predominantly used DSM-IV criteria, although studies that measured CUD in other ways 
(ICD, CUDIT, DSM-5) were included.  
 
Treatment of Cannabis Use Disorders  
Treatment demand for cannabis use is increasing globally in every region except Africa 
(UNODC, 2019). In Europe, 155,000 individuals entered treatment for problems related to 
cannabis in 2017, with over half entering treatment for the first time (Montanari et al., 2017; 
European Monitoring Centre for Drugs and Drug Addiction, 2019). A possible contributor to 
these changes is the increase in cannabis potency in recent decades (Freeman et al., 2020a) 
which has been associated with elevated treatment admissions for CUDs (Freeman et al., 
2018). In fact, cannabis is now responsible for more first time admissions than any other drug 
in Europe (Figure 1; European Monitoring Centre for Drugs and Drug Addiction, 2019). A 
typical client entering drug treatment for cannabis initiates use at age 17, enters treatment at 
25, and uses cannabis 5.3 days per week at treatment entry.  
 
Whilst these treatment data are indicative of the extent of problematic use in the population, 
prevalence of CUD is much greater and it is estimated that over 85% of individuals with 
lifetime CUD do not seek treatment (Hasin et al., 2016). In Europe, there is considerable 
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variation by country in estimates of unmet cannabis treatment needs. While treatment provision 
is high in some countries (e.g. Germany, Norway) where one in ten daily users receive 
treatment, it is low in others (including Italy, Spain and France) where one to three of every 
100 daily users receive treatment (Schettino et al., 2015). In a large survey of adults with CUD 
in the US, 10.28% had received drug treatment of any kind in the past year, with only 7.81% 
having received cannabis-specific treatment (Wu et al., 2017). 
 
Psychosocial treatments (Table 1) 
There is good evidence that psychosocial treatments can be effective for the treatment of 
cannabis use disorders. Treatment options are often not developed specifically for use in CUD 
and many have been adapted from existing substance use treatments (Schettino et al., 2015). 
Cognitive Behavioural Therapy (CBT) and Motivational Enhancement Therapy (MET) can 
reduce frequency and intensity of cannabis use as well as symptoms of dependence, in 
comparison to inactive control, and can be delivered in combination (Gates et al., 2016). For 
example, an RCT of 10-week combined CBT, MET and problem solving training treatment 
(n=149) compared to delayed treatment control (n=130) was conducted at 11 outpatient 
treatment centres in Germany (Hoch et al., 2014). Compared to control, treatment improved 
rates of self-reported abstinence and urinary-verified abstinence at post-treatment, though 
reported abstinence rates decreased at 6-month follow-up in the treatment group. Treatment 
also impacted the number of ICD-10 cannabis dependence criteria met at post-treatment, 
however rates of dependence or abuse were low in the sample at baseline (56.3 and 8.6%, 
respectively).  
 
Psychotherapies are appropriate in adolescent samples, and inclusion of the patient’s family in 
treatment may be particularly effective. For example, an international multi-site RCT (Rigter 
et al., 2013) found that a 6 month programme of Multidimensional Family Therapy (n=212) 
reduced cannabis dependence in adolescents better than individual psychotherapy (n=238) over 
the same time period, with a significantly greater shift from dependence to abuse or no CUD 
in the family therapy group. 
 
Brief versions of MET have also been investigated, primarily in school based settings, to 
ascertain whether psychosocial treatment can be employed without lengthy and intensive 
treatment intervention (Walker et al., 2011). In one such RCT from the USA, adolescents 
received 2 sessions of MET, and were then randomly assigned to a motivational check in 
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(n=128) or assessment- only check in (n=124), with extra CBT sessions offered but not 
enforced (Walker et al., 2016). The two sessions of MET reduced cannabis use in both 
conditions, with the motivation check-in group showing a larger reduction in days of use and 
fewer symptoms at 6-months, however this was not sustained at 9- or 12- month follow up.  
 
Evidence suggests that adding contingency management (CM) of monetary incentives for 
abstinence outcomes to combined CBT + MET can increase the likelihood of reducing cannabis 
frequency and achieving abstinence into longer term follow ups (Kadden et al., 2007). In fact, 
evidence from RCTs in the USA suggests that CM alone can reduce cannabis use more 
effectively than CBT during the treatment period. For example, (Budney et al., 2006) found 
the average number of weeks of continuous abstinence during treatment were significantly 
superior in a CM-only condition (n=30) than CBT (n=30), and adding CBT to CM did not offer 
any additional benefit (n=30). However, the analysis of continuous abstinence was 
underpowered and therefore potentially important differences between groups may not have 
been detected. This was mirrored in findings by (Kadden et al., 2007) who found a CM-only 
condition to have superior rates of abstinence at post-treatment to MET-CBT in a large 
(n=240), 9-week RCT from the US, though abstinence rates then declined after 5 months. 
Combined MET-CBT and CM yielded the longest periods of continuous abstinence during the 
follow-up year and resulted in the greatest proportion of individuals abstinent at 11- and 14-
month follow-up. 
 
Finally, there is evidence of small treatment effects for digital interventions on reducing 
cannabis use (Hoch et al., 2016). The most promising results come from an RCT conducted in 
Germany (Tossmann et al., 2011) that employed online discussion with a trained 
psychotherapist, including weekly personalised feedback based on CBT (n=863), compared to 
waiting list (n=429). The treatment group showed a greater reduction in days of use over the 
last 30 days compared to waiting list as well as reduced quantity of cannabis used at follow-up 
conducted 3-months after enrolment on the programme. However, these analyses were not 
sufficiently powered due to low engagement and high dropout rates. Preliminary evidence from 
an RCT conducted in the USA showed that a 4-week text-delivered treatment reduced the 
proportion of the sample reporting cannabis-related relationship problems (n=51) significantly 
more than an assessment-only control (n=50). However, there was no reduction in frequency 
of cannabis use (Mason et al., 2018). Further, retention was high with 96% of participants 
completing 3-month follow-up. Digital interventions so far have produced mixed findings, but 
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given their potential for tackling barriers to treatment engagement, larger trials assessing their 
reduction in cannabis use as well as diversity of population they can reach are warranted. 
Further digital interventions such as smartphone apps show promise in this area (Albertella et 
al., 2019) and have the potential to reach the substantial number of people who do not seek in 
person treatment for CUDs at present.  
 
Pharmacological treatments (Table 2) 
A 2019 Cochrane review concluded that there were no high-quality indications of an effective  
pharmacological treatment for CUD based on available evidence (Nielsen et al., 2019). Since 
the publication of this review there have been several new trials of pharmacological treatment 
of CUDs (D’Souza et al., 2019; Lintzeris et al., 2019; Freeman et al., 2020b). Moreover, the 
Cochrane review based its recommendations on abstinence achieved at the end of treatment. 
However, expert consensus recommends that sustained abstinence should not be considered 
the primary outcome for all clinical trials of CUD (Loflin et al., 2020).  
 
Substitution cannabinoid treatments  
Several studies have investigated the effects of Dronabinol (synthetic THC) or Nabiximols 
(THC and CBD at 1:1 ratio) for the treatment of CUD and/or cannabis withdrawal. An RCT 
conducted in the USA (Levin et al., 2011) found that 40mg daily Dronabinol (Treatment n=70, 
Placebo n=77) in combination with MET was superior to placebo at reducing severity of 
withdrawal symptoms but not rates of 2-week abstinence. Days of cannabis use measured via 
an extensive TLFB method was also not significantly different between Dronabinol and 
Placebo. Additionally, a 2-site inpatient detoxification trial in Australia (Allsop et al., 2014; 
Treatment n=27, Placebo n=24) of six days Nabiximols combined with MET/CBT was found 
to reduce withdrawal, and improve treatment retention, but was not associated with greater 
reduction in cannabis use. Further a pilot, outpatient RCT in Canada (Trigo et al., 2018) found 
no significant difference in frequency of cannabis use or withdrawal symptoms for 12-week 
treatment of flexible Nabiximols use combined with weekly MET/CBT (n=20) compared to 
MET/CBT alone (n=20). The Nabiximols group reduced their tobacco use over the trial. A 
multi-site, outpatient RCT conducted in Australia (Lintzeris et al., 2019) tested 12-week 
flexible Nabiximols treatment with 6 sessions of CBT (n=64) compared to placebo and 6 
sessions of CBT (n=73). Contrasting with previous findings, Nabiximols reduced frequency of 
cannabis use during the trial compared to placebo but did not significantly reduce cannabis 
withdrawal over placebo. These results were sustained at 12-week follow-up (Lintzeris et al., 
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2020). This study monitored nicotine and alcohol dependence over the treatment period and 
found no change over time or any group differences. Overall, evidence suggests that 
substitution treatments containing THC typically reduce withdrawal symptoms but evidence 
for their effectiveness at reducing cannabis use is mixed and may depend on the setting and 
duration of treatment.   
 
Non-substitution cannabinoid treatments 
Trials have also tested alternative pharmacological treatments acting on the endocannabinoid 
system (Parsons and Hurd, 2015). A Phase II RCT involving 5 day enforced-abstinence 
followed by four-week treatment with the FAAH inhibitor PF-04457845 (n=46; D’Souza et 
al., 2019) compared to placebo (n=24) found reductions in self-reported use of cannabis at the 
end of treatment, and THC:COOH concentrations, as well as reduced cannabis withdrawal 
symptoms on the first and second day of enforced abstinence. As PF-04457845 did not have 
sufficient safety data in females at the time of this study, only male participants were included. 
These safety data are now available, and a subsequent Phase III trial (n=273) including males 
and females is currently underway. Finally, a Phase IIa adaptive Bayesian RCT conducted in 
the UK (Freeman et al., 2020b) tested CBD at daily doses of 200mg, 400mg, 800mg versus 
placebo for four weeks alongside six sessions of motivational interviewing. CBD was more 
efficacious than placebo at reducing cannabis at daily doses of 400mg or 800mg (posterior 
probabilities > 0.9) but not 200mg (posterior probability <0.1). Cannabis use measured via self-
report and urinary THC:COOH was reduced compared to placebo (n=23) following 400mg 
(n=24) and 800mg (n=23) CBD. Reductions in cannabis use were maintained up to 24-week 
follow up with 400mg CBD but not 800mg CBD. These results suggest a possible inverted-U 
dose-response curve effect of CBD on cannabis use, consistent with CBD effects on anxiety 
(Zuardi et al., 2017). Longer follow-ups and RCTs specifically designed to determine efficacy 
are required to extend these results. Both FAAH inhibitors and CBD can increase 
concentrations of the endocannabinoid anandamide (Leweke et al., 2012; D’Souza et al., 
2019). These non-substitution cannabinoid treatments offer possible strategies to treat CUDs 
through endocannabinoid system mechanisms, without risk of harm from THC administration.  
 
Other pharmacological treatments 
An RCT from the USA investigating N-acetylcysteine added on to contingency management 
treatment has shown effectiveness at treating CUD in adolescents (Gray et al., 2012). Those 
receiving N-acetylcysteine treatment (n=58) were 2.4 times more likely to submit a negative 
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urinary screen for cannabis use compared to placebo (n=58). There was no significant 
difference in change of days with self-reported cannabis use across the trial between groups. 
Contrasting results were found in a subsequent multi-site RCT of adults with CUD (Gray et 
al., 2017) where negative urinary screens were not statistically different between N-
acetylcysteine (n= 153) and placebo (n=149). These treatment effects were not moderated by 
sex, ethnicity or tobacco smoking status. However, baseline tobacco use was a significant 
predictor of negative cannabis outcomes in general, with tobacco smokers half as likely to 
achieve abstinence from cannabis in both groups. These findings illustrate the importance of 
considering tobacco use in the treatment of CUD. 
 
There is some evidence for the effectiveness of gabapentin in the treatment of CUD from an 
RCT in the USA (Mason et al., 2012). Gabapentin together with abstinence-oriented 
counselling demonstrated superiority at 1200mg/day for 12 weeks (n=25) over placebo (n=25), 
at reducing cannabis use as verified through reduced self-reported grams of cannabis, fewer 
self-reported days of cannabis use and reduced urinary THC-COOH concentrations as well as 
lower cannabis withdrawal severity. However, a limitation was high levels of drop out in the 
trial (n=18 for Gabapentin; n=14 for placebo). Moreover, a larger trial (Mason, 2017) of 
Gabapentin 1200mg/day for 12 weeks (n=75) did not demonstrate efficacy compared to 
placebo (n=75).  
 
In summary, substitution cannabinoid treatments containing THC appear effective at 
reducing cannabis withdrawal but evidence has been mixed for changes in cannabis use. 
Other treatments targeting the endocannabinoid system (FAAH inhibition and CBD) and N-
acetylcysteine (in adolescent, but not adults) show proof of concept evidence for reducing 
cannabis use, but require replication in larger trials. 
 
 
Psychosis (Table 3) 
A Cochrane review published in 2014 concluded that there is a lack of good quality evidence 
for the efficacy of any psychosocial or pharmacological treatment at reducing cannabis use in 
psychosis (McLoughlin et al., 2014). Studies conducted since the publication of that review 
have had mixed findings (Smeerdijk et al., 2012; Rabin et al., 2018; Sheridan Rains et al., 
2019). Tailored and time-intensive cannabis-focused treatment plans have not provided better 
outcomes than treatment as usual (Wisdom et al., 2011). For example, a superiority trial 
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conducted in Denmark using weekly motivational interviewing and CBT targeted specifically 
at patients with psychosis who continued to use cannabis (n=52), found similar reductions in 
cannabis use at the end of treatment and follow up as treatment as usual (n=51), targeted only 
towards psychotic disorder (Hjorthoj et al., 2013). 
 
A small feasibility study of Canadian males found that supportive therapy alongside a $300 
payment for 28 day abstinence was associated with 68.4% of patients with CUD and 
schizophrenia (n=19), reporting abstinence, compared to 95% of patients with CUD-only 
(n=20) reporting abstinence. However, negative urinary screens were only present in 47.3% of 
patients with schizophrenia, and 40% in CUD-only (Rabin et al., 2018). Replication of these 
findings has not been achieved in subsequent RCTs to date. A large (n=551, treatment n=278), 
multi-centre RCT from the UK (Sheridan Rains et al., 2019) investigating the addition of a 
voucher-incentive programme to early intervention psychosis treatment did not find a 
difference in the primary outcome of time to admission to an acute mental health service, and 
no difference on self-reported cannabis use at the end of treatment.  
 
Finally, a trial conducted in the Netherlands demonstrated that a family motivational 
intervention (Parents n=53, Patients n=37) which focuses on establishing a supportive family 
environment, compared to routine family support (Parents n=44, Patients n =38) was effective 
at reducing frequency and quantity of cannabis use in adolescent and young adult patients with 
schizophrenia at 3 month follow-up (Smeerdijk et al., 2012). This was sustained at 15-month 
follow-up (Smeerdijk et al., 2015). There were no significant changes from baseline in use of 
alcohol or any other drugs other than cannabis during this trial.  
 
Overall, RCT data suggests that psychosocial treatments that appear effective in CUD-only 
patients (including contingency management) do not appear effective for patients with 
comorbid psychosis. However, involvement of the family in treatment appears successful in 
some patients and is a possible strategy for future research. In addition to psychosocial 
treatments, the effects of digital interventions are currently unclear, but a targeted, self-guided 
web-based programme is currently being trialled for young people with psychotic experiences 
and cannabis use in Australia (Hides et al., 2020). 
 
Evidence for the role of pharmacological treatments for CUDs in people with psychosis is 
lacking at present. A systematic review found preliminary evidence that some antipsychotic 
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medications might be effective at reducing both cannabis use and psychotic symptoms 
(Wilson and Bhattacharyya, 2015). Both clozapine (n=14) and ziprasidone (n=16) were 
associated with significant reduction in cannabis use and psychotic symptoms (PANSS 
positive), in a pilot study conducted in Germany (Schnell et al., 2014). Further evidence from 
(Machielsen et al., 2011) suggests that olanzapine treatment (n=52) is associated with lower 
cannabis craving in comparison to risperidone (n=48) in patients with psychotic disorder and 
cannabis dependence as measured using the craving subscale of the Obsessive Compulsive 
Drug Use Scale. However, this comparison used cross-sectional data from a larger study 
conducted in the Netherlands rather than an RCT design. Altogether, evidence suggests that 
standard antipsychotic treatment for psychosis may have additional benefits for patients with 
comorbid CUD. Future research should consider whether any additional treatment options are 
efficacious to further support these patients. Further, other pharmacological treatments that 
have been investigated in CUD have not been explored in comorbid psychosis, so their 
efficacy in these patients is unknown at present.  
 
Pharmacological management of CUD and psychosis should consider interactions between 
cannabis and prescribed antipsychotic medication (Brzozowska et al., 2017). Such drug-drug 
interactions may account for poor antipsychotic medication adherence, which mediated the 
effects of cannabis use on relapse to psychosis in a two-year prospective observational study 
(Schoeler et al., 2017). Emerging evidence strongly implicates the endocannabinoid system 
in psychosis (Minichino et al., 2019) as well as addiction (Curran et al., 2016) which presents 
a promising target for future treatments. Antipsychotic treatments which act on the 
endocannabinoid system (CBD) have produced favourable outcomes (Leweke et al., 2012; 
McGuire et al., 2017). One possible strategy is CBD for the treatment of comorbid CUD and 
psychosis (Batalla et al., 2019). Due to the poor efficacy of psychosocial interventions for 
comorbid CUD and psychosis, and the poor clinical outcomes associated with continued 
cannabis use in this population, the development of effective pharmacological treatments is 
an urgent priority. 
 
 
Anxiety and depression (Table 4) 
A large multisite RCT in the USA (Buckner and Carroll, 2010) reported that 9 sessions of CBT 
tailored to CUD (n=156) compared to 2-session MET alone (n=146) reduced anxiety and that 
reduction was correlated with successful reduction in CUD. Further, a small pilot trial 
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conducted in the USA combining cannabis-tailored MET-CBT with transdiagnostic anxiety 
treatment (ICART, n =27) showed preliminary evidence of increased rates of abstinence at the 
end of treatment over MET-CBT alone as confirmed using urinalysis. Targeted treatments for 
depression have also been investigated. For example, a study from Australia (Kay-Lambkin et 
al., 2009) found that motivational interviewing plus CBT treatment tailored for both depressive 
symptoms and comorbid cannabis use (SHADE, n=67) resulted in significant overall 
reductions in cannabis use over 12 months, and reductions in depressive symptoms compared 
to a brief intervention (n=97). There is no current evidence for an effective pharmacological 
treatment for both depression and CUD. SSRIs have been investigated as a treatment for CUD, 
and have not proven efficacious (Weinstein et al., 2014; McRae-Clark et al., 2016). Moreover, 
trials investigating fluoxetine and venlafaxine specifically for comorbid depression and CUD, 
have not found improvement in CUD or depression in comparison to placebo (Cornelius et al., 
2010; Levin et al., 2013).  
 
Taken together, it appears feasible to target comorbid CUD with anxiety or depression 
effectively with psychosocial treatment and this should be encouraged. To date, 
pharmacological treatments specifically targeting CUD comorbid with anxiety or depression 
have not been successful. 
 
Summary of findings and critical appraisal 
Current evidence suggests that psychosocial treatments including CBT, MET and CM can 
increase duration of abstinence from cannabis, reduce frequency of cannabis use, and reduce 
symptoms of CUD, and their combination may yield most effective results over the long-term. 
Trials of psychosocial interventions benefit from large sample sizes and multi-site designs, 
which increase power and generalisability. Of note, clinical trials of psychosocial interventions 
typically employ waiting list or low-intensity treatments as a control intervention. This could 
artificially inflate the effect sizes observed in such trials (Furukawa et al., 2014) due to a lack 
of expectancy from a matched placebo, alongside negative effects of psychosocial control 
conditions (“nocebo” effects), and this should be considered when interpreting findings across 
different trial designs.   
 
Psychosocial treatment interventions are generally associated with positive during-treatment 
effects, though these attenuate at follow-up and long-term clinical efficacy needs to be assessed 
with longer follow-up periods. Most interventions encourage complete abstinence from 
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cannabis use, but are flexible towards individual goals. Sustained abstinence does not occur for 
the majority of patients. Further evidence is required to compare the efficacy of emerging 
digital interventions to in-person treatment, and to address the high dropout level observed in 
online interventions. Research is required to assess whether digital interventions could tackle 
some of the key barriers to treatment seeking in CUD including stigma and desire for more 
informal treatment options.  
 
Several trials have investigated substitution treatments (medications containing THC) to treat 
CUD or aid in detoxification from cannabis. Generally, these trials observe high rates of 
reduction of cannabis in both treatment and placebo groups, likely due to a beneficial effect of 
the paired psychotherapies typically employed in experimental and control conditions in these 
trials. This should be considered when comparing the efficacy of pharmacological treatments 
with psychosocial treatments, as pharmacological treatments are tested as adjunctive therapies 
which may limit their potential to provide additional benefits to an effective psychosocial 
intervention. Additionally, based on the current evidence it is not clear whether psychosocial 
treatments are necessary in order to promote retention in CUD trials or to facilitate the efficacy 
of pharmacotherapies. Future trials should aim to investigate the additive or synergistic effects 
of psychosocial and pharmacological treatments in order to maximise efficacy and cost-
effectiveness. Moreover, pharmacological trials are often based on small sample sizes with 
shorter follow-up periods, a reflection of their currently early phase of assessment.  
 
Despite this, treatments are associated with increased retention as well as reduction in 
withdrawal symptoms, though lack of longer-term follow-ups creates difficulty in assessing 
whether the beneficial impact on reducing withdrawal symptoms translates to meaningful 
clinical outcome in the long-term. Other pharmacological treatment strategies targeting the 
endocannabinoid system including CBD and FAAH inhibition show promise, but require 
replication in larger RCTs with longer follow-up durations. 
 
An important consideration when evaluating findings across trials is that treatment outcome is 
defined in many different ways. Typically, likelihood or duration of abstinence is included as 
a primary indicator of treatment success. However, reductions in frequency and quantity of use 
also mark a positive treatment response, especially when biological measures such as urinalysis 
are employed to quantify use (Loflin et al., 2020). For shorter-term interventions, reduction in 
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cannabis craving or withdrawal may represent positive treatment response in the absence of 
reduction in cannabis use.  
 
Further, the majority of trials discussed in this review were conducted in samples of >70% 
male participants. Consequently, the impact of sex on treatment outcomes in CUD is unclear. 
This is important as women experience more rapid escalation of problems from first use to 
CUD than men, even when matched for age at first or heavy use (Khan et al., 2013; Crocker 
and Tibbo, 2018). Women also experience more withdrawal symptoms and greater 
withdrawal severity than men (Herrmann et al., 2015). Increasing female participants in 
RCTs for CUD treatment, as well as investigating sex as an a priori moderator of treatment 
efficacy and safety is needed to establish sex-specific treatment recommendations for clinical 
practice. Further, mental health comorbidities are frequently used as exclusion criteria, which 
means these samples are likely not representative of the wider population of people with 
CUD who might respond differently to treatment. Similarly, most trials exclude participants 
with another substance use disorder (SUD), other than nicotine and caffeine. Where such 
comorbidities are not an exclusion criterion, they are often not assessed throughout the 
treatment period and subsequently their impact on treatment outcome is not explored. SUDs 
commonly overlap with CUD, and also with other mental health disorders (Hasin et al., 
2016). Comorbid SUDs can also impact on treatment need and efficacy. For example co-
occurring cannabis and tobacco use is associated with increased likelihood of developing 
CUD, as well as poorer cessation treatment outcomes including relapse to cannabis use 
(McClure et al., 2020). Ascertaining the impact of comorbidities on efficacy of treatment for 
CUD is vital to be able to personalise treatment options depending on the patient’s mental 
health and substance use profile.   
 
Taken together, our recommendations for future interventions for CUD are to ensure that 
studies are sufficiently powered, in particular by considering recruiting sufficiently large 
sample sizes to deal with dropout observed in interventions for CUD. Further, researchers 
should consider whether findings replicate in populations with CUD and mental health 
comorbidities. Trials should ensure that follow-ups have been planned with sufficient duration 
to assess whether treatment effects persist following treatment completion. Finally, primary 
endpoints assessing sustained reduction in cannabis use should be employed alongside, or 




Another consideration for future research is the large proportion of individuals not seeking out 
or accessing treatment who may benefit from it. Among non-treatment seeking users with 
cannabis dependence, lack of motivation (not believing anyone could help the problem, 
wanting to handle the problem alone) has been found to be a major contributor to not seeking 
treatment (Khan et al., 2013). Stigma also appears as a common barrier to treatment, with 
individuals reporting feeling embarrassed about seeking treatment. Desire to be self-reliant as 
well as preference for informal treatment options has also been identified in non-treatment 
seeking users with cannabis dependence (van der Pol et al., 2013) which may indicate 
advantages of digital interventions compared to more intensive treatment programmes. Further, 
improving the information available about treatment services as well as simplifying treatment 
admission processes have been identified as perceived facilitators of treatment (Gates et al., 
2012). Finally, access and affordability of drug treatment options could create a significant 
barrier to treatment engagement, particularly in countries such as the US. Therefore, increasing 
access, acceptability and perhaps variety of treatments is an important goal for alleviating the 
adverse effects of untreated CUDs. These factors may also relate to individuals’ willingness to 
take part in clinical trials of interventions for CUD, and may partially explain high rates of 
dropout suffered in such trials e.g. (Mason et al., 2012). Future research should work directly 
with individuals seeking treatment for CUD, to expand our understanding of the acceptability 
of current treatment options as well as exploring which factors facilitate treatment seeking.  
 
Finally, this review highlights the particular challenges of treating CUD in people with mental 
health comorbidities. For example, contingency management appears effective in those with 
CUD, however trials have not replicated this effect in those with comorbid psychosis. Most 
pharmacological interventions have not been explored in people with mental health 
comorbidities. The lack of efficacious treatments in this population highlights a major unmet 
clinical need at present. Antipsychotic medication also could play an important role in the 
management of comorbid CUD and psychosis, with some medications such as clozapine and 
olanzapine associated with a reduction in cannabis craving. Psychosocial treatments targeting 
dual diagnosis appear beneficial for management of CUD with anxiety and depression. While 
mental health comorbidities are common in people with CUD, evidence on the efficacy of 
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Table 1. Study design and primary endpoint data for psychosocial interventions for CUD 
Study Interventions Primary endpoint(s) 
Hoch et al., 
2014 
CBT + MET + Problem solving 
(n= 255), 10-week 
 
Delayed treatment control 
(n= 130), 8-week 
CBT + MET+ problem solving intervention increased rates of urinary-verified 7-day 
abstinence from baseline to end of treatment (11.7% - 46.3%), a greater increase than the 
delayed treatment control (9.3% - 17.7%), p<.001. 
 
Urinary-verified 7-day abstinence rates in the CBT + MET + problem solving group were 
32.4% at 3 months, and 35.7% at 6 months. Urinary-verified abstinence rates for delayed 
treatment control at 3 and 6 months not provided as they had entered treatment.  
 
Rigter et al., 
2013 
Multidimensional family therapy 
(n= 212), 6-month 
 
Individual psychotherapy  
(n= 238), 6-month 
Multidimensional family therapy increased retention in treatment (90% therapist-reported 
completion) compared to individual psychotherapy (48% therapist-reported completion), 
p<.001.  
 
Multidimensional family therapy reduced prevalence of diagnosis of either cannabis abuse 
or dependence from baseline to 12-month follow-up (100% - 71%), a non-significant change 
compared to individual psychotherapy (100% - 74%).  
 
Multidimensional family therapy reduced past-90 day cannabis use from baseline to 12-
month follow-up [59.8(25.3) – 34.0(32.6)] a non- significant decrease compared to 




2 session brief MET + 




2 session brief-MET + assessment 
only check-in (4-, 7-, 10- month) 
(n= 124) 
Motivational check-in intervention reduced past-60 day use from baseline to 6-month 
[36.80(15.16) – 26.64(20.25)], a greater reduction in use than the assessment-only check-in 





(n= 30), 14-week 
Contingency Management produced significantly greater weeks of continuous abstinence 





(n= 30), 14-week  
 
CBT+ Contingency Management  
(n= 30), 14-week  
Management did not produce a significant difference in continuous abstinence [5.3(4.7)] 
compared to Contingency Management alone. 
 
Contingency management alone, and combined with CBT yielded a greater percentage of 
patients achieving 6 or more weeks of abstinence during treatment than CBT alone 





CBT + MET (n= 61), 9-week 
 
CBT + MET + CM (n= 63), 9-
week 
 
CM (n= 54), 9-week 
 
Case Management (n= 62), 9-
week 
Treatment interventions did not significantly differ in achieved proportion of days abstinent 
at 2-month or further follow-ups. Contingency management produced a significantly greater 




Web-based treatment  
(n= 863), 50-day  
 
Waiting List 
(n= 429), up to 3 months 
 
Web-based treatment produced a greater reduction in last-30 day frequency of cannabis use 
from baseline to 3-month follow up [25.1(6.9) – 16.5(20.9)] compared to waiting list 
[25.3(6.5) – 21.0(17.1)], p<.001. 
 
Web-based treatment produced a greater reduction in quantity of use in last 30 days from 
baseline to 3-month follow up [21.7(19.9) – 13.1(29.7)] compared to waiting list 




Peer-network counselling text 
treatment  
(n = 51), 4-week 
 
Assessment-only control  
(n= 50), 4-week  
Peer-network text intervention reduced past-30 day use from baseline to end of treatment, 
[24.2(6.1) – 20.8(8.5)] which was not significantly different to assessment-control [23.9(6.2) 
– 20.2(8.6)].  
 
Peer-network text reduced prevalence of cannabis-related relationship problems from 
baseline to 3 month follow up (53% - 11%), a greater increase than in the assessment-




Table 2. Study design and primary endpoint data for pharmacological interventions for CUD 
 
Study Interventions Primary endpoint(s) 
Levin et al., 
2011 
Dronabinol 20mg (n = 79), 12-
week (one-week placebo lead-in, 
one week titration, 6-week 
medication maintenance, 2-week 
taper dose, 2-week placebo lead 
out) 
 
Placebo (n= 77), 12-week 
 
Both interventions paired with a 
weekly coping skills psychosocial 
intervention 
 
Dronabinol did not significantly influence rates of 2-week abstinence compared to placebo 
at the end of treatment (17.72% vs 15.58%).  
 
 
Allsop et al., 
2014 
Nabiximols (n =27), 6-day in-
patient detoxification (Day 1 = 
43.2 THC + 40mg CBD, Days 2-
3 = max 86.4mg THC, 80mg 
CBD, Day 4 = max 64.8mg THC, 
60mg CBD, Day 5 = 10.8mg 
THC, 10mg CBD, Day 6 = 5.4mg 
THC, 5mg CBD) 
 
 
Placebo (n =24), 6-day in-patient 
detoxification 
 
Nabiximols treatment produced a  reduction in scores on the Cannabis Withdrawal Scale 
from onset of treatment to days 2-6, [2.51 (1.57) - 1.88 (1.64)], which was significantly 
greater than the placebo group [1.68 (0.96) - 2.22 (1.62)], p=.01.  
 
Patient retention was greater during the inpatient detoxification in the Nabiximols group 
(85% remained in treatment at day 6) vs the placebo group (50% remained in treatment at 
day 6), p=.02.  
27 
 
Both interventions paired with 
CBT-based self-completed 
workbook and guided 
psychotherapy  
Trigo et al., 
2018 
Nabiximols, self-titrated: range 
from 11g THC + 10.2mg CBD – 
34.5mg THC + 31.9mg CBD (n= 
20), 12 week  
 
Placebo (n= 20), 12-week  
 
Both paired with weekly 
MET/CBT  
Nabiximols treatment did not significantly influence cannabis use compared to placebo in 7-
day point prevalence of abstinence after the medication phase (30.8% vs 42.9%). 
 Lintzeris et 
al., 2019 
Nabiximols, (n = 64) 12-week; 3-
day dose induction period, then 
maximum daily dose 86.4mg 
THC + 80mg CBD, doses titrated 
at weekly clinical interview 
 
Placebo (n= 73), 12-week 
 
Both paired with 6-week CBT 
counselling   
Nabiximols treatment produced a reduction infrequency of cannabis use during treatment 
(mean 35/84 days), compared to placebo (mean 53.1/84 days), p=.02.  
D’Souza et 
al., 2019 
PF-04457845, 4mg once daily 
(n=46), 5-8 days inpatient, 20-23 
day outpatient phase 
 
Placebo (n=24), 5-8 days 
inpatient, 20-23 day outpatient 
phase 
PF-04457845 treatment produced significantly reduced cannabis withdrawal symptoms on 
Day 0 (6.04 vs 11, p=.048) and Day 1 (6.02 vs 11.74, p=.035) but not Day 2 (8.78 vs 9.54, 
p=.709), Day 3 (6.80 vs 8.74, p=.812) or Day 4 (7.65 vs 9.04, p =.979) of inpatient 
treatment, compared to placebo.  
 
PF-04457845 treatment reduced cannabis use (joints per day) at week 4 [0.40(0.25 – 0.62)] 




PF-04457845 treatment significantly reduced urinary THC-COOH levels at week 4 







200mg CBD (n=12), 4-week  
(group eliminated at interim 
analysis) 
 
400mg CBD (n = 24), 4-week 
 
800mg CBD (n=23), 4-week 
 
Placebo (n=23), 4-week  
 
All groups paired with 6 sessions 
of motivational interviewing  
400g CBD decreased urinary THC:COOH at the end of treatment (posterior 
probability=0.9995; -94.21 ng/ml; 95% CI: -161.83, -35.56), as well as increased days 
abstinent (posterior probability=0.9966; +0·48 days per week; 95% CI: 0.15, 0.82), 
compared to placebo. 
 
800mg CBD decreased urinary THC:COOH at the end of treatment (posterior 
probability=0.9965; -72.02 ng/ml; 95% CI: -135.47, -19.52), and increased days abstinent 
(posterior probability=0.9247; +0.27 days per week, 95% CI: -0.09, 0.64), compared to 
placebo.  
 
Gray et al., 
2012 
N-acetylcysteine, 2400mg daily 
(n=58), 8-week 
 
Placebo (n=58), 8-week  
 
Both paired with twice-weekly 
contingency management  
N-acetylcysteine increased the odds of a negative urine test for cannabis use during the 
treatment period compared to placebo (40.9% vs 27.2%), OR= 2.4 (1.1-5.2), p=.029.  
Gray et al., 
2017 
N-acetylcysteine, 2400mg daily 
(n=153), 12-week 
 
Placebo (n=149), 12-week  
 
Both paired with twice-weekly 
contingency management 
N-acetylcysteine treatment did not influence the odds of a negative urine test for cannabis 





Gabapentin 1200mg daily (n 
=25), 12-week 
 
Placebo (n =25), 12-week  
 
Both paired with weekly 
abstinence-oriented counselling  
Gabapentin treatment significantly reduced grams of cannabis per week at the end of 
treatment compared to placebo (p=.004) 
 
Gabapentin treatment was significantly reduced in urinary THC-COOH at the end of 






Table 3. Study design and primary endpoint data for targeted interventions for comorbid CUD and psychosis 




interviewing and CBT tailored for 
cannabis-related problems + 
treatment as usual (n =52), 6-
month 
 
Treatment as usual (n =51), 6-
month  
CapOpus treatment did not influence the ratio of days with cannabis use compared to 
treatment as usual [0.76, (95% CI 0.38–1.50] p=0.42.  
Rabin et al 
2018 
Contingency management in 
schizophrenia patients (n = 19) 
 
Contingency management in non-
psychiatric controls (n =20)  
 
Both paired with weekly 
supportive therapy including 
motivational interviewing, 
psychoeducation and coping skills 
Contingency management produced 68.4% self-reported abstinence during treatment in 
schizophrenia patients, compared to 95% in the control patients.  
 
Contingency management produced 47.3% urinary-confirmed abstinent in schizophrenia 
patients, compared to 40% of control patients.  
Sheridan-
Rains et al., 
2019  
Contingency management + 6 
session psychoeducation (n = 
278), 12-week 
 
Psychoeducation (n =273), 12-
week  
Contingency management treatment was not associated with reduced time to admission to 





et al 2015 
Family Motivational Intervention 
(Parents n =53; Patients n =37), 6-
month 
 
Routine family support (Parents n 
=44; Patients n =38), 6 month 
Family motivational intervention reduced mean days of cannabis use from baseline to 3-
month follow-up [56.12(28.55) – 15.24(25.45)], compared to routine family support [52.88 





Clozapine average daily dose 
225mg (n =14), 12-month  
 
Ziprasidone average daily dose 
200mg (n =16), 12-month 
 






Clozapine did not reduce frequency of cannabis use (joints per month) compared to 
Ziprasidone, p=.128.  
Machielsen 
et al 2012 
Cross-sectional analysis of cohort 
study data  
Risperidone, mean dose 3.45mg 
(n= 48) 
 
Olanzapine, mean dose 13.78mg 
(n= 52) 
 
Clozapine, mean dose 350mg (n= 
23)  
OCDUS (Obsessive Compulsive Drug Use Scale) total score was higher in patients who had 
been prescribed risperidone (1.83) compared to Olanzapine (1.54) or Clozapine (1.33), 
p=.005. 
 
Scores on the “Craving” subscale of the OCDUS were higher in patients who had been 





Table 4. Study design and primary endpoint data for targeted interventions for comorbid CUD and anxiety or depression 




 MET + CBT, 9 session (n =156), 
12 week 
 
MET, 2 sessions (n =146), 1- and 
5- week post-randomisation  
 
Delayed treatment control (n 
=148), 4-month   
 
 
MET + CBT treatment produced significantly lower STAI anxiety scores compared to MET 
at 4-months [30.80(0.90) vs 33.59(0.96)], and 9-months [30.64(0.86) vs 34.36(0.92)] p<.05.  
Buckner et 
al., 2019  
ICART (MET-CBT tailored for 
cannabis and anxiety), 12 session 
(n =27), 12-week  
 
MET-CBT (tailored for reduction 
of anxiety), 9 session (n =28), 12-
week  
ICART treatment produced greater completion of 9-sessions of treatment* (59.3%) than 
MET-CBT (25%), p=.010.  
 
*endpoint chosen as the greatest number of weeks that could be compared due to MET-CBT 
treatment having fewer sessions than ICART.  
 
Negative urinary tests for cannabis were not significantly different between conditions 





9 session tailored therapist-
delivered CBT(n=35), 3-month 
 
9 session tailored computer-
delivered CBT (n=32), 3-month 
 
Brief intervention only (n=30), 
one session  
Therapist-delivered CBT produced improvements in depression from baseline to 12-month 
[34.9(9.7) – 20.35(14.49)] compared to brief intervention [32.86(9.59) – 24.76(12.55)]. 
Computer-delivered CBT also produced improvements in depression from baseline to 12 -
month [28.57(9.89) – 13.65(9.55)] compared to the brief intervention. 
 
Therapist-delivered CBT produced a reduction in cannabis use occasions per day from 
baseline to 12 months [15.03(13.87) – 5.72(6.22)] compared to brief intervention 
[9.22(8.57) – 8.61(10.16)], p <.001. Computer delivered CBT also produced a reduction in 
cannabis use occasions per day from baseline to 12 months [11.94(9.14) – 3.34(5.52)], 






Fluoxetine, starting dose 10mg 
daily, increased to 20mg target 
dose at week 3 (n=34), 12-week 
 
Placebo (n=36), 12-week 
 
Paired with nine session of CBT 
+ MET   
  
Fluoxetine treatment reduced BDI total scores from baseline to end of treatment 
[18.06(8.80) – 7.79(7.98)], a non-significant decrease compared to placebo [16.64(9.85) – 
7.31(8.29)], p=.803.   
 
Fluoxetine treatment decreased days of cannabis used per week from baseline to end of 
treatment [4.61(2.18) = 3.88(2.60)] a non-significant reduction compared to placebo 
[4.35(1.93) – 3.10(2.27)], p=.182.  
 
Fluoxetine treatment reduced DSM-IV-TR cannabis dependence from baseline to end of 
treatment [4.88(1.63) – 3.29(2.11)] a non-significant reduction compared to placebo 
[5.19(1.35) – 3.14(1.74), p =.738.   
Levin et al., 
2013 
Venlafaxine, 225mg daily, max 
37mg day after week 4, (n=51), 
12-week 
 
Placebo (n=52), 12-week  
 
Paired with weekly CBT and 
relapse prevention treatment  
Venlafaxine treatment resulted  in 11.8% of the sample achieving 2 consecutive urine-
confirmed abstinent weeks, significantly less than achieved in the placebo group (36.5%), 
p<.001.  
 
Venlafaxine treatment resulted in 62.7% achieving a 50% reduction of Hamilton depression 
score at end of study, a non-significant difference from the placebo group (69.2%), p=.51.  
 
Venlafaxine treatment resulted in  51% achieving a score <8 on the Hamilton Depression 
Rating Scale at the end of treatment, a non-significant difference from the placebo group 
(57.7%), p=.33.  
   
 
